Extensive research has provided substantial insight into the neurobiological mechanisms underlying the reinforcing, locomotor-activating and stereotypy-inducing actions of psychostimulants. The diverse behavioral effects of these drugs are superimposed on potent arousalenhancing actions. Psychostimulant-induced arousal is a prominent contributing factor to the widespread use and abuse of these drugs. Moreover, enhanced arousal may be a critical component of the reinforcing and other behavioral actions of these drugs. Although long overlooked, recent work begins to identify the neural mechanisms involved in psychostimulant-induced arousal. For example, microdialysis studies demonstrate a close relationship between amphetamine-induced waking/arousal and amphetamine-induced increases in norepinephrine and dopamine efflux. Additionally, it is now clear that both norepinephrine and dopamine exert robust wakepromoting actions. The wake-promoting effects of norepinephrine involve synergistic actions of a 1 -and b-receptors, whereas dopamineinduced waking involves both D1 and D2 receptors. Finally, additional studies have identified subcortical regions involved in the wakepromoting actions of both norepinephrine and amphetamine. These regions include, but may not be limited to, the medial septal area, the medial preoptic area, and the lateral hypothalamus. Combined, these and other observations indicate a prominent involvement of both norepinephrine and dopamine in stimulant-induced arousal via actions within a network of subcortical regions. Although it is clear that both norepinephrine and dopamine contribute to psychostimulant-induced arousal, the degree to which each transmitter system is necessary for the expression of stimulant-induced arousal remains to be fully elucidated.
INTRODUCTION
Psychostimulants influence a variety of cognitive, affective, and motor processes. Extensive research conducted over the past three decades has provided substantial insight into the neurobiological mechanisms underlying the reinforcing, locomotor-activating and stereotypy-inducing actions of these drugs. The diverse behavioral effects of stimulants are superimposed on potent arousal-enhancing actions. The arousal-enhancing properties of psychostimulants are a prominent contributing factor to the widespread use and abuse of these drugs. Moreover, there exists a close relationship between arousal and state-dependent affective and cognitive processes (Bindra, 1968; Pribram and McGuinness, 1975) . Thus, drug-induced arousal may well be an integral component of the broader spectrum of the behavioral actions of psychostimulants. Given the prominent nature of psychostimulant-induced arousal, it is surprising that little is known regarding the neural mechanisms underlying stimulant-induced arousal.
NEUROBIOLOGY OF AROUSAL
The term 'arousal' typically refers to the extent to which an organism is sensitive and/or responsive to information arising from the environment (Pribram and McGuinness, 1975) . Across the sleep-wake cycle, large fluctuations in the sensitivity to sensory information are observed (Evarts, 1960; Pfingst et al, 1977; Bushnell et al, 1981) . Further, within waking, sensitivity to environmental stimuli also varies, ranging from relative inattentiveness/insensitivity associated with drowsiness to extreme sensitivity (hypersensitivity) under conditions of intense arousal (Davis, 1997; Aston-Jones et al, 1998) .
Changes in behavioral indices of arousal are accompanied by alterations in forebrain neuronal activity that are reflected in electroencephalographic (EEG) signals (TimoIaria et al, 1970; Vanderwolf and Robinson, 1981; Makeig and Inlow, 1993; McCormick and Bal, 1997) . The formal examination of the neural mechanisms underlying arousal dates back to the work of Bremer (1937) and Moruzzi and Magoun (1949) , which identified a critical role of the brainstem in arousal. To date, numerous systems have been identified that participate in the regulation of EEG and/or behavioral activity state, including brainstem (ie noradrenergic, serotonergic, cholinergic, hypocretin, etc) and basal forebrain systems (Foote et al, 1980; Hobson et al, 1975; Vanderwolf and Robinson, 1981; Metherate et al, 1992; O'Donnell, 2003; Steriade and Buzsaki, 1990 ; Buzsaki et al, 1988; Berridge and O'Neill, 2001; Sutcliffe and de Lecea, 2002) .
NORADRENERGIC AND DOPAMINERGIC MODULATION OF BEHAVIORAL STATE: OVERVIEW
Stimulants increase extracellular levels of norepinephrine (NE), dopamine (DA), and to varying degree, serotonin (for a review see, Kuczenski and Segal, 1994) . Importantly, the qualitative and quantitative neurochemical actions of these drugs are dependent on both the identity and dose of drug (Kuczenski and Segal, 1994) . For example, cocaine potently affects serotonergic neurotransmission, whereas amphetamine (AMPH) increases extracellular serotonin levels only at moderately high doses and methylphenidate has minimal impact on serotonin across a broad range of doses (Kuczenski and Segal, 1997) . Combined, these observations indicate that enhanced serotonergic neurotransmission is not an essential mechanism underlying the arousal-enhancing actions of psychostimulants, although this may contribute to the arousal-enhancing actions of certain stimulants.
Given that all psychostimulants target NE and DA neurotransmission, a critical first question becomes whether NE and DA exert arousal-enhancing actions. In examining the involvement of a neurotransmitter system in the regulation of behavioral state (or any other process), there are two potential general approaches. The first examines the effects of enhancing the activity of that neurotransmitter, whereas the second examines the effects of blocking the actions of that transmitter. Importantly, each approach addresses fundamentally distinct questions. In the first, the extent to which a transmitter is sufficient to induce a change in behavioral state is examined. In the second, the extent to which a transmitter is necessary for the maintenance of a behavioral state is examined. The neural regulation of arousal appears to involve substantial redundancy, with multiple systems exerting wake-promoting actions (Vanderwolf and Robinson, 1981; Pape and McCormick, 1989; Berridge and Waterhouse, 2003) , and thus, inactivation of any single system often has minimal effects on sleep-wake state. This redundancy suggests that negative effects of neurotransmitter-selective antagonists and/or lesions on sleep and waking need to be interpreted cautiously.
Noradrenergic Modulation of Behavioral State
The locus coeruleus (LC) is the major source of brain NE (Foote et al, 1983) . Synaptically released NE produces its effects in LC terminal fields via interactions with three major NE receptor subtypes: a 1 , a 2 , and b. a 1 -and breceptors are thought to exist primarily postsynaptically, whereas a 2 -receptors are present both pre-and postsynaptically. LC neurons display a tonic mode of discharge activity characterized by highly regular and state-dependent activity, with highest rates occurring during waking and lower rates during sleep (Hobson et al, 1975; Foote et al, 1980; Aston-Jones and Bloom, 1981) . During waking, LC neurons discharge most rapidly in anticipation of EEG and behavioral changes that signal enhanced arousal or attentiveness (Foote et al, 1980; Aston-Jones and Bloom, 1981) . Consistent with these observations, in vitro, NE induces a shift in activity patterns of cortical/thalamic neurons from a burst-mode typically associated with slow-wave sleep to a single spike-mode typically associated with waking (McCormick et al, 1991) .
Combined, these observations suggest a causal role for the LC in the regulation of arousal/behavioral state. Consistent with this hypothesis, acute suppression of LC-NE neurotransmission by systemic, i.c.v., or intra-brainstem administration of a 2 -agonists results in profound sedation (De Sarro et al, 1987; Gatti et al, 1988; Waterman et al, 1988) . The small size of the LC and the close proximity of this nucleus to other brainstem arousal-related nuclei makes it difficult to determine unambiguously whether these drug-induced alterations in arousal involve actions on the LC-NE system or adjacent structures. To better address this issue, additional studies examined the effects of selective manipulation of LC neuronal activity on EEG indices of forebrain arousal in halothane-anesthetized rats. These studies utilized electrophysiological recordings to guide the placement of small infusions (35-150 nl) of pharmacological agents within close proximity to the LC to increase or decrease the rate of LC discharge activity (Adams and Foote, 1988) . The effect of drug-induced alterations in LC neuronal discharge activity on forebrain EEG activity patterns was then examined (Berridge and Foote, 1991; Berridge et al, 1993) . The close proximity of the infusion needle to the LC permits the use of small infusion volumes and thus limits the spread of drug beyond the LC. In these studies, unilateral LC activation produced a robust and relatively rapid (5-10 s) bilateral activation of forebrain EEG in the halothane-anesthetized rat (see Figure 1 ). This LC-dependent activation of forebrain EEG was prevented with i.c.v. pretreatment of a b-antagonist (Berridge and Foote, 1991) . Conversely, bilateral suppression of LC neuronal discharge resulted in a robust increase in slowwave EEG activity under baseline conditions associated with EEG activation (ie lightly anesthetized preparation; Berridge et al, 1993) . Importantly, even minimal LC neuronal discharge activity within a single hemisphere (ie 5-10% of basal levels) was sufficient to maintain bilaterally forebrain activation. This likely explains why LC/noradrenergic lesions, which almost certainly never reduce completely Figure 1 Relationship of LC neuronal discharge activity to cortical EEG activity before, during, and after peri-LC bethanechol infusions in the halothane-anesthetized rat. Bethanechol was infused 300-400 mm lateral to LC while LC neuronal activity was recorded. Simultaneously, EEG was recorded from the frontal cortex. EEG activity is shown in the top trace and the raw trigger output from LC activity in the bottom trace. Bethanechol infusion elicits an increase in LC discharge rate, which is readily apparent approximately two-thirds of the way through the 60-s infusion. Several seconds following LC activation, an abrupt onset of EEG desynchronization is observed (see Berridge and Foote, 1991) . extracellular NE levels (Abercrombie and Zigmond, 1989; Castaneda et al, 1990) , do not result in large alterations in time spent awake (for a review see, Berridge and Waterhouse, 2003) . Combined, these observations indicate that the LC is a potent modulator of forebrain and behavioral activity states.
NE Acts at b-and a 1 -Receptors Located Within the Medial Septal Area and the Medial Preoptic Area to Promote Alert Waking
There exist a variety of cortical and subcortical sites where LC efferents might act to modulate forebrain EEG. Within the basal forebrain, the general regions of the medial septal area (MSA), the substantia innominata (SI), and the medial preoptic area (MPOA) participate in the regulation of forebrain EEG activity state (Buzsaki et al, 1983 (Buzsaki et al, , 1988 Mohan et al, 1984; Metherate et al, 1992) . Each of these regions receives LC-noradrenergic input Zaborszky et al, 1991; Swanson and Hartman, 1975; España and Berridge, 2006) . Pharmacological mapping studies in unanesthetized, sleeping rats demonstrate robust dose-dependent and additive EEGactivating and wake-promoting actions of b-and a 1 -receptor stimulation within the MSA and MPOA, but not the SI (Figure 2 , also Figure 6 ; Berridge and O'Neill, 2001 ). Based on these observations, it is concluded that the activation of b-and a 1 -receptors within the MSA and the MPOA likely contributes to stimulant-induced arousal. It is important to note that as used here, the terms MSA and MPOA refer to heterogeneous structures, each containing multiple subnuclei. The anatomical resolution of these previous mapping studies (approximately 500 mm) precludes identification of the specific subnuclei involved in the wakepromoting actions of NE within these general regions.
b-Receptors are not Necessary for the Maintenance of Alert Waking
The above-described observations demonstrate that the stimulation of MSA and MPOA b-receptors is sufficient to produce behavioral and forebrain EEG activation in anesthetized and unanesthetized animals. Moreover, in the anesthetized animal, both the global blockade of b-receptors, via i.c.v. infusions of a b-antagonist, and the selective blockade of MSA b-receptors, via intratissue infusions of a b-antagonist, decrease EEG activation under conditions of elevated LC discharge rates (Berridge and Wifler, 2000) . These observations indicate that b-receptors, including the subset located within the MSA, are necessary for forebrain EEG activation under these conditions (ie in the presence of anesthesia; Berridge and Wifler, 2000) .
In contrast, in the unanesthetized rat, neither i.c.v. infusions of a b-antagonist (Berridge and España, 2000) or bilateral blockade of MSA b-receptors reduce EEG and behavioral indices of arousal (Berridge and Wifler, 2000) . As mentioned, in unanesthetized animals, the global suppression of LC-NE neurotransmission (using i.c.v. or intrabrainstem-administered a 2 -agonists) decreases EEG/ behavioral indices of arousal, indicating a necessary role for NE in normal arousal (De Sarro et al, 1988; Danysz et al, 1989) . Combined, these observations indicate that in the unanesthetized animal, actions of other NE receptor subtypes (ie a 1 -receptors) make the arousal-promoting actions of b-receptors redundant in the unanesthetized animal (see 'Synergistic actions of b-and a1-Receptors in the Maintenance of Alert Waking' below, for further discussion). It is important to emphasize that redundancy does not imply irrelevance: under normal conditions, stimulation of b-receptors (including MSA b-receptors) will promote alert waking, a functionally important action.
The LC is not the Sole Source of Noradrenergic Innervation to the MSA and MPOA Evidence described above indicate that LC neurons exert robust modulatory actions on forebrain activity state and that this involves, at least in part, actions of NE within the MSA and MPOA. However, there are a number of noradrenergic nuclei that could also provide input to the MSA and MPOA, and thus could also promote the alert waking state. Recently completed retrograde tracing studies demonstrate that although the LC provides the majority of noradrenergic input to these three regions (approx. 50%), lesser, although at times substantial, contributions arise from the A1/C1 (approx. 25%) and A2/C2 (approx. 25-40%) adrenergic cell groups (España and Berridge, 2006) . In contrast, the subcoeruleus and A5 provide minimal input to the MSA and MPOA. Because these studies did not differentiate between adrenergic and noradrenergic cell bodies, these numbers likely overestimate the noradrenergic contribution from A1/C1 and A2/C2. Nonetheless, these observations indicate that a substantial proportion of + Po0.05 compared to PRE1 (see .
noradrenergic input to the MSA and MPOA originates from outside the LC. Given the potent wake-promoting actions of MSA and MPOA NE receptors, it appears reasonable to conclude that A1/C1 and A2/C2 noradrenergic/adrenergic systems exert arousal-enhancing actions via projections to the MSA and MPOA. A logical extension of this conclusion is that stimulant-induced arousal likely involves actions of the A1/C1 and A2/C2 noradrenergic/adrenergic systems in addition to the LC-NE system.
Additional Regions Involved in NE-Dependent Waking
The observations reviewed above indicate a prominent role of the MSA and the MPOA in NE-and stimulant-induced arousal. However, numerous additional brain regions have been implicated in the regulation of arousal state. Included among these is the lateral hypothalamus (LH), a region that has long been hypothesized to play a role in the regulation of state and state-dependent processes, including motivation and reward (Stellar, 1954; Olds, 1962) . More recently, it has been demonstrated that this region is the primary source for the peptide transmitter, hypocretin/orexin, which exerts robust wake-promoting actions when administered centrally (España et al, 2001; Sutcliffe and de Lecea, 2002) . The LH receives a moderately dense noradrenergic innervation (Baldo et al, 2003) , although most of this arises from outside the LC (Yoshida et al, 2005) . In preliminary studies, we have observed wake-promoting actions of the a 1 -agonist, phenylephrine, when infused into the LH, but not when infused immediately outside this region. These observations indicate that NE-dependent waking may well involve the LH. In addition to the MSA, MPOA, and LH, there are a number of regions that participate in the regulation of arousal level (ie central nucleus of the amygdala, tuberomammillary nucleus), all of which receive a relatively robust noradrenergic innervation. These observations indicate that both NE-and stimulant-induced arousal involve an extended network of multiple subcortical regions, the complete details of which remain to be determined.
Synergistic Actions of b-and a 1 -Receptors in the Maintenance of Alert Waking
The above-reviewed observations indicate that stimulation of either a 1 -or b-receptors is sufficient for the induction of alert waking. This raises the question of the extent to which the combined actions of these receptors are necessary for alert waking (ie contribute to the maintenance of the alert waking state). This question was addressed in studies that examined the EEG effects of b-receptor blockade (timolol, i.c.v.), a 1 -receptor blockade (prazosin, intraperitoneally), or both b-and a 1 -receptor blockade under conditions associated with high arousal level (ie brightly lit novel environment; Berridge and España, 2000) . When administered separately, b-receptor blockade has minimal effects on EEG and behavioral indices of arousal, whereas a 1 -receptor blockade results in an increase in sleep spindles (Figure 3 ; Buzsaki et al, 1991) . In contrast, blockade of both b-and a 1 -receptors results in a profound increase in large-amplitude, slow-wave EEG activity (Figure 3) . Thus, combined blockade of b-and a 1 -receptors exerts synergistic sedative effects.
Synergistic arousal-modulatory actions of a 1 -and breceptors could, in part, explain why earlier studies examining the effects of a single NE receptor antagonist failed to detect substantial alterations in psychostimulantinduced behavior. Importantly, the sedative effect of combined a 1 -and b-receptor blockade was not observed during the first 5-min of testing. Thus, under certain conditions of elevated arousal, the combined activation of a 1 -and b-receptors is not necessary for the maintenance arousal. The degree to which combined actions of a 1 -and breceptors is necessary for stimulant-induced arousal remains to be determined.
Wake-Promoting Actions of DA
Compared to the LC-NE system, less information exists regarding the degree to which central DA systems modulate behavioral state. Interestingly, midbrain DA neurons do not display robust alterations in firing rate between sleep and quiet waking (Steinfels et al, 1983; Trulson and Preussler, 1984) . Nonetheless, rates of DA release within DA terminal fields fluctuate with sleep-wake state (Trulson, 1985; Smith et al, 1992; Feenstra et al, 2000) . Moreover, systemic administration of D1 receptor agonists and antagonists increase and decrease, respectively, time spent awake (Monti et al, 1990; Trampus et al, 1991) . D2 receptor agonists exert more complex effects, likely reflecting both presynaptic and postsynaptic functions of this receptor family (Monti et al, 1989; Python et al, 1996; Lagos et al, 1998; Olive et al, 1998) . When administered centrally (i.c.v.) in sleeping rats, the D1 agonist, SKF-82958, and the D2 agonist, quinpirole, produce dose-dependent increases in time spent awake and suppress REM and slow-wave sleep in . In contrast to that observed with b-receptor blockade alone, in the presence of a 1 -receptor blockade, b-receptor blockade produced substantial increases in large-amplitude, slow-wave activity (see Berridge and España, 2000) .
the absence of locomotor activation (Figure 4 ; Isaac and Berridge, 2003) . Given stimulants enhance DA efflux widely throughout the brain; these and other observations (Nishino et al, 1998; Wisor et al, 2001 ) suggest a prominent role of DA in the wake-promoting actions of these drugs.
INVOLVEMENT OF NE AND DA IN STIMULANT-INDUCED AROUSAL
Available evidence indicates wake-promoting actions of both NE and DA. Given the robust actions of psychostimulants on NE and DA neurotransmission, this in turn provides strong evidence for the involvement of both NE and DA in the arousal-enhancing actions of psychostimulants. Nonetheless, delineating the relative contribution of NE and/or DA in stimulant-induced arousal is particularly challenging for a number of reasons. First, systemic administration of NE and DA antagonists can influence behavioral state via peripheral actions. Further, given that multiple NE and DA receptors exert wake-promoting actions, blocking the actions of a single receptor may not impact substantially stimulant-induced arousal. Similarly, given a variety of regions appear to participate in stimulantinduced arousal, blocking the actions of NE and/or DA within a single region may not have a material impact on the arousal-enhancing actions of these drugs. Nonetheless, as reviewed below, limited observations collected to date provide evidence for a role of both NE and DA in stimulantinduced arousal.
AMPH Acts within the Basal Forebrain to Increase Arousal
Given that NE a 1 -and b-receptors act within the MSA and MPOA to promote waking, it was proposed that these regions participate in psychostimulant-induced arousal. Consistent with this hypothesis, AMPH infusion into, but not outside (including SI), these regions elicits sustained increases in EEG and behavioral indices of arousal/waking ( Figure 5 ; Berridge et al, 1999) . For both the MSA and MPOA, the arousal-enhancing actions of AMPH were dosedependent (Berridge et al, 1999) . Relative to unilateral infusions, bilateral infusions produced greater behavioral activation. At the lower dose of AMPH tested, AMPHinduced waking appeared to resemble normal waking, and was not associated with increases in locomotor activity or stereotypy. In contrast, bilateral infusions of the highest dose examined produced substantial increases in locomotor activity. In preliminary studies, we have also observed wake-promoting actions of AMPH when infused into the LH (data not shown). Combined, these observations indicate psychostimulant-induced arousal involves an extended network of subcortical sites that include, but is unlikely limited to (see above), the MSA, MPOA, and LH.
AMPH-Induced Increases in Arousal and NE and DA Release are Closely Related
If NE and/or DA participate in stimulant-induced arousal, there should be a close relationship between stimulantinduced alterations in NE/DA efflux and arousal.
In vivo microdialysis studies demonstrate the existence of just such a relationship for both NE and DA (Berridge and Stalnaker, 2002) . In these studies, low doses of AMPH (0.15, 0.25 mg/ kg) that promote waking but do not produce locomotor activation/stereotypy produced prominent increases in extracellular levels of NE within the PFC that were closely associated with drug-induced increases in time spent awake ( Figure 6 ). PFC DA was not as responsive as PFC NE to mild arousal produced by brief handling of the animal or during the earliest periods of AMPH-induced waking. Nonetheless, in general, there was a close relationship between AMPHinduced waking and AMPH-induced increases in PFC DA efflux ( Figure 6 ). Overall, these studies support the hypothesis that the arousal-enhancing actions of low-dose psychostimulants, in part, derive from stimulant-induced increases in NE and DA release. These studies measured NE and DA efflux within the PFC because the PFC receives a noradrenergic innervation solely from the LC and because evidence suggests that at higher doses, stimulants produce comparable actions on NE/DA efflux across distinct catecholaminergic terminal fields. However, it was recently observed that at low doses that do not promote waking, the stimulant, methylphenidate, increases NE and DA efflux within the PFC while having minimal effects on subcortical NE (MSA) and DA (accumbens) efflux . At modestly higher doses associated with moderate increases in time spent awake, more prominent increases in NE and DA efflux were observed outside the PFC. Combined, these observations suggest that (1) low-dose stimulants can preferentially target NE/DA neurotransmission within the PFC, and (2) Po0.05 compared with the low dose of the respective drug (see Isaac and Berridge, 2003) .
Neurobiology of stimulant-induced arousal CW Berridge stimulant-induced arousal is more closely linked to stimulant-induced alterations in NE and DA neurotransmission outside the PFC, particularly within select subcortical regions (ie MSA, MPOA, LH). It is possible that a failure to significantly impact subcortical NE neurotransmission could, at least in part, explain why wake-promoting actions have not been observed with all NE reuptake blockers (ie if the dose was too low to increase NE efflux within these subcortical regions; Nishino et al, 1998) .
Is AMPH-Induced Arousal Dependent on NE?
The above-reviewed information indicates that stimulantinduced increases in NE neurotransmission contribute to stimulant-induced arousal. Unaddressed in this work is the degree to which NE is necessary for full expression of stimulant-induced arousal. As an initial step in testing the hypothesis that NE is indeed necessary for AMPH-induced arousal, the effects of i.c.v. pretreatment with the bantagonist, timolol, on intravenous (i.v.) AMPH (0.15 mg/ kg)-induced EEG activation were examined in halothaneanesthetized rats (Berridge and Morris, 2000) . It was observed that timolol pretreatment dose-dependently blocked AMPH-induced EEG activation (Figure 7) . Thus, in the anesthetized animal, blockade of central b-receptors is sufficient to block the EEG activating effects of systemic AMPH. The effects of b-antagonist on AMPH-induced arousal in the unanesthetized animal remain to be examined. However, the above-described observations indicate that in contrast to anesthetized animals, b-receptor blockade alone does not reduce EEG or behavioral indices of arousal in unanesthetized animals. Therefore, it is predicted that b-receptor blockade alone will not alter AMPH-induced arousal in the unanesthetized animal. However, given the sedative effects of combined blockade of both a 1 -and b-receptors in unanesthetized animals, it is quite possible that combined actions of these two receptors is necessary for full expression of stimulant-induced arousal. Figure 6 Relationship between AMPH-induced increases in waking and AMPH-induced increases in extracellular levels of NE and DA (bottom panel). Unanesthetized animals were treated with 0.15 mg/kg (subcutaneously) AMPH. Shown are the NE (top panel) and DA (bottom panel) levels (pg/20 ml) from 15-min dialysate samples and time spent awake. Scales have been adjusted to permit the superimposition of NE and waking data from baseline and recovery portions of the AMPH response. There was a close relationship between AMPH-induced changes in waking and NE and DA levels (see Berridge and Stalnaker, 2002) . BST, bed nucleus of the stria terminalis; CC, corpus callosum; CP, caudate-putamen; GP, globus pallidus; I, internal capsule; LS, lateral septum, LC, lateral ventricle; MS, medial septum; NA nucleus accumbens; NDB, nucleus of the diagonal band; SI, substantia innominata (see Berridge et al, 1999) .
Is AMPH-Induced Arousal Dependent on DA?
Direct stimulation of NE receptors within a variety of subcortical regions promotes alert waking. Thus, it is likely that NE contributes to stimulant-induced arousal. However, previous studies demonstrate that the deletion of the DA transporter (DAT) gene in mice prevents the wakepromoting effects of methamphetamine (Wisor et al, 2001) . Combined, these observations could indicate that stimulant-induced increases in extracellular levels of DA are necessary for the expression of NE receptor-dependent waking. However, this hypothesis is hard to reconcile with robust wake-promoting actions of intratissue infusions of direct acting NE agonists, which presumably occur in the absence of drug-induced increases in DA neurotransmission. Alternatively, as described above, stimulant-induced arousal likely involves the actions of NE and DA outside the PFC. For example, at low doses, methylphenidate preferentially targets NE and DA neurotransmission within the PFC and this is associated with minimal increases in time spent awake . Given the mild wakepromoting effects observed in wild-type animals in the DAT knockout study (an increase of 60-min over a 5-h period), the dose of methamphetamine used in this study appears relatively low. Therefore, it is possible that this relatively low dose of methamphetamine had a minimal impact on extracellular NE levels outside the PFC. It will be important for future studies to determine the degree to which both NE and DA are necessary for the arousalenhancing actions of psychostimulants.
SUMMARY
Despite the robust and well-documented arousal-enhancing effects of psychostimulants, surprisingly little is known regarding the neural mechanisms underlying these actions. Available evidence indicates prominent arousal-enhancing actions of both NE and DA via action within a variety of subcortical sites, including the MSA, MPOA, and LH. Given stimulants enhance NE and DA efflux, these observations indicate a prominent role of both NE and DA acting in these subcortical sites in stimulant-induced arousal. Consistent with this hypothesis, stimulant-induced arousal appears to be closely related to drug-induced alterations in NE and DA efflux within these subcortical regions. Moreover, when infused directly into these subcortical regions, AMPH exerts robust wake-promoting actions. Combined, the available evidence indicates that psychostimulant-induced arousal is dependent on the actions of both NE and DA within a widely distributed network of subcortical regions.
